Sequential immunization with antigens from different strains of HIV-1, influenza viruses or dengue viruses induced cross-neutralizing antibodies and enhanced the antibody responses against previous antigens. The characteristics of neutralizing antibodies induced by sequential immunization with different types of HPV L1VLPs are unclear. In this study, mice were primed with one or two types (HPV16 or HPV16/18) of L1VLPs, then boosted sequentially with HPV6/18/45/11/31/58 or HPV6/45/11/31/58 L1VLPs, and sera were analyzed with HPV pseudovirus-based neutralization assay. The results showed that neutralizing activities against earlier immunized vaccine types were enhanced gradually by subsequent immunizations, and low levels of neutralizing activities against non-vaccine types (HPV33/35/52/59/68) were also observed. After absorbing the immune sera with vaccine type (HPV16/18/45) L1VLPs, neutralizing activities against tested priming and boosting types (HPV16/18/58) decreased significantly, and that against non-vaccine type (HPV33) were also partially eliminated. Moreover, neutralizing activities against vaccine types (HPV16/58) were significantly reduced after absorbing with non-vaccine-type VLPs (HPV33/52). These data suggest that cross-neutralizing epitopes exist among different HPV L1VLPs. The cross-neutralizing activities against non-vaccine types and the enhanced neutralizing activities against earlier immunized vaccine types may be resulted from sequential boosting with these cross-neutralizing epitopes. These observations support for early vaccination with more types of L1VLPs derived from HPVs that cause serious threat to population. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.
April 19, 2018
A Comparison of Imaging Software and Conventional Cell Counting in Determining Melanocyte Density in Photodamaged Control Sample and Melanoma In Situ Biopsies.
March 12, 2020
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- ENDO: 2020ENDO 2020 Annual Conference has been canceled due to COVID-19. Here are highlights of emerging data that has still been released. Keep an eye out for ENDO Online 2020, which will take place from June 8 to 22.